Genetic Screening May Prevent Adverse Gout Treatment Reaction

Screening for HLA-B*58:01 is especially attractive for its extremely high, negative predictive value. HLA-B*58:01 can also be used for a broader spectrum of ethnic groups, including Thai, Japanese, Korean and European groups. However, the prevalence of HLA-B*58:01 may still need to be better defined in these populations.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: National prospective cohort study. BMJ. 2015 Sep 23;351:h4848. doi: 10.1136/bmj.h4848.

The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

“Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

Be careful when prescribing allopurinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

Difficult Gout

Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Related Articles